NCT07554560 Nutrition Intervention for Pancreatic Cancer
| NCT ID | NCT07554560 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Children's Hospital of Philadelphia |
| Condition | Pancreatic Ductal Adenocarcinoma (PDAC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 18 participants |
| Start Date | 2026-04-07 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 18 participants in total. It began in 2026-04-07 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (NET)) commonly experience fat malabsorption due to exocrine pancreatic insufficiency (EPI) and leads to gastrointestinal (GI) symptoms, malnutrition, weight loss, and reduced quality of life (QoL). Current standard treatment, pancreatic enzyme replacement therapy (PERT), is limited by suboptimal adherence, high cost, and partial effectiveness to prevent fat malabsorption. The objective of the study is to assess the feasibility and maintenance of lipid absorption function of a structured lipid medical food (SLMF; Encala®) powder in subjects with PDAC and NET with EPI.
Eligibility Criteria
Inclusion Criteria: * Pancreatic ductal adenocarcinoma or pancreatic neuroendocrine tumor diagnosis and age greater than or equal to 18 years * Life expectancy of 4 months or greater * Oral or enteral tube feeding for \> 60% daily calories * For patients with NET, evidence of GI dysfunction such as \>5% unintentional weight loss, increased number of bowel movements¸change in stool consistency (e.g., soft stool or diarrhea), as documented in the medical record and confirmed by the treating oncologist. Exclusion Criteria: * Pregnant or lactating * Unable to consume food by mouth (oral intake) * Allergy to soy lecithin product ingredients * Psychosocial environment for which study participation may be difficult for subject or family, as confirmed by medical team * Military service members, Reserve Service members, National Guard members, Department of Defense (DoD) civilians, and DoD contractors * Patients with diminished capacity to consent
Contact & Investigator
Virginia A Stallings, MD
PRINCIPAL INVESTIGATOR
Children's Hospital of Philadelphia
Frequently Asked Questions
Who can join the NCT07554560 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Ductal Adenocarcinoma (PDAC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07554560 currently recruiting?
Yes, NCT07554560 is actively recruiting participants. Contact the research team at appiahe@chop.edu for enrollment information.
Where is the NCT07554560 trial being conducted?
This trial is being conducted at Philadelphia, United States, Philadelphia, United States.
Who is sponsoring the NCT07554560 clinical trial?
NCT07554560 is sponsored by Children's Hospital of Philadelphia. The principal investigator is Virginia A Stallings, MD at Children's Hospital of Philadelphia. The trial plans to enroll 18 participants.